TABLE 1.

Summary of current suggestions for withholding oral anti‐hyperglycaemic medication in patients with diabetes and COVID‐19

Medication	Suggested withholding in patients with COVID‐19
Metformin	Temporarily withhold while unwell due to risk of lactic acidosis (S62, S66, S83, S86)
SGLT2‐I empagliflozin, dapagliflozin, canagliflozin, ertugliflozin	Temporarily withhold while unwell due to risk of diabetic ketoacidosis (S62, S66, S80, S83, S86)
Sulphonylureas gliclazide, glipizide, glibenclamide, tolbutamide, chlorpropamide	Temporarily withhold while unwell due to risk of hypoglycaemic events (S86)
GLP‐1 receptor agonists liraglutide, dulaglutide, exenatide	Continue with close monitoring (S62) OR temporarily withheld while unwell (S66, S90) due to risk of volume contraction
DPP4i sitagliptin, vildagliptin, saxagliptin, linagliptin	Consider withholding saxagliptin and alogliptin in critically unwell patients due to risk of exacerbated heart failure (S71). Continuation of DPP4i in mild disease may be considered (S62)

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.